OncoMatch/Clinical Trials/NCT06854445
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Is NCT06854445 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TQB2825 for diffuse large cell b-lymphoma.
Treatment: TQB2825 — The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 positive expression (positive)
Pathological diagnosis results containing CD20 positive expression
Required: MYC rearrangement negative (negative)
Myc rearrangement negative after anti-CD20 treatment must be provided
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
Subjects with relapsed or refractory diffuse large B-cell lymphoma who have received at least 1 line of systemic therapy
Must have received: anti-CD20 therapy
Myc rearrangement negative after anti-CD20 treatment must be provided
Cannot have received: antibody drugs targeting CD3 and CD20 at the same time
previous use of other antibody drugs targeting CD3 and CD20 at the same time
Cannot have received: CAR-T cell therapy
Exception: within 3 months before the first dose
received Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy, or other immune cell therapy, or autologous hematopoietic stem cell transplantation (auto-HSCT) within 3 months before the first dose
Cannot have received: immune cell therapy
Exception: within 3 months before the first dose
received Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy, or other immune cell therapy, or autologous hematopoietic stem cell transplantation (auto-HSCT) within 3 months before the first dose
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 3 months before the first dose
received Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy, or other immune cell therapy, or autologous hematopoietic stem cell transplantation (auto-HSCT) within 3 months before the first dose
Cannot have received: R-GemOx
previous treatment with R-GemOx
Cannot have received: GemOx
previous treatment with ... GemOx
Cannot have received: chemotherapy
Exception: 4 times before the first dose, or still within 5 half-lives of the drug
received chemotherapy, immunotherapy, monoclonal antibody therapy 4 times before the first dose, 2 times received radiotherapy or small molecule targeted drugs, or subjects who are still within 5 half-lives of the drug, the washout period is calculated from the end time of treatment
Cannot have received: immunotherapy
Exception: 4 times before the first dose, or still within 5 half-lives of the drug
received chemotherapy, immunotherapy, monoclonal antibody therapy 4 times before the first dose, 2 times received radiotherapy or small molecule targeted drugs, or subjects who are still within 5 half-lives of the drug, the washout period is calculated from the end time of treatment
Cannot have received: monoclonal antibody therapy
Exception: 4 times before the first dose, or still within 5 half-lives of the drug
received chemotherapy, immunotherapy, monoclonal antibody therapy 4 times before the first dose, 2 times received radiotherapy or small molecule targeted drugs, or subjects who are still within 5 half-lives of the drug, the washout period is calculated from the end time of treatment
Cannot have received: radiotherapy
Exception: 2 times before the first dose
2 times received radiotherapy or small molecule targeted drugs
Cannot have received: small molecule targeted drugs
Exception: 2 times before the first dose
2 times received radiotherapy or small molecule targeted drugs
Cannot have received: Chinese patent medicines with clear anti-tumor indications
Exception: 2 times before the first dose
received treatment with Chinese patent medicines with clear anti-tumor indications in the package insert of National Medical Products Administration (NMPA)-approved drugs 2 times before the first dose
Lab requirements
Blood counts
Laboratory tests meet specific criteria; failure to recover from adverse reactions to CTCAEv5.0 criteria ≤ grade 1 from previous treatment excluded
Kidney function
Renal failure requiring hemodialysis or peritoneal dialysis, previous history of nephrotic syndrome excluded
Liver function
Laboratory tests meet specific criteria; decompensated cirrhosis (Child-Pugh class B or C liver function) and active hepatitis excluded
Cardiac function
Have major cardiovascular disease excluded
Laboratory tests meet specific criteria; decompensated cirrhosis (Child-Pugh class B or C liver function) and active hepatitis excluded; Renal failure requiring hemodialysis or peritoneal dialysis, previous history of nephrotic syndrome excluded; Have major cardiovascular disease excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify